CD4 and COVID-19: Surveying the literature on CD4+ T cell epitopes in either individuals who were unexposed or patients recovered/recovering from COVID-19 circa November 2020, we selected 29 peptides using evidence of immunogenicity in cohorts containing HLA-DR1 positivity combined with predicted binding to HLA-DR1 according to NetMHCIIpan35 (Table 1).